U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07209332) titled 'Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy' on Aug. 14.
Brief Summary: This is a Phase 2 open-label extension (OLE) study to evaluate the long-term safety, tolerability, efficacy, pharmacokinetics, and the pharmacodynamics (PD) through potential exploratory biomarker(s) of intravenous (IV) WVE-N531 in patients with DMD who participated in another study of WVE-N531. All patients will have rolled over from a previous study of WVE-N531.
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Duchenne Muscular Dystrophy
Intervention:
DRUG: WVE-N531
WVE-N531 is an antisense oligon...